Company > Strategy
Acacia Pharma aims to become a leading hospital pharmaceutical organisation, selling products directly to anaesthetists and oncologists in the US. The key elements of this strategy are:
- Complete the registration for the Group’s lead product candidate, BARHEMSYS® (amisulpride injection) for the prophylaxis and treatment of PONV;
- Directly commercialise BARHEMSYS® (amisulpride injection) in the US through its own sales and marketing infrastructure;
- Establish strategic partnerships for the commercialisation of its products with companies outside the US that have expertise, sales and marketing infrastructure, initially focusing on the major pharmaceutical markets, e.g. Europe; and
- Leverage the Group’s future US commercial infrastructure to sell APD403 for CINV to oncologists and consider in-licensing or acquiring complementary products or product candidates.